• Novocure Ltd NVCR.OQ reported a quarterly adjusted loss of 61 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of seven analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -44 cents to -27 cents per share.

• Revenue rose 20.5% to $161.27 million from a year ago; analysts expected $157.81 million.

• Novocure Ltd's reported EPS for the quarter was a loss of 61 cents​.

• The company reported a quarterly loss of $65.92 million.

• Novocure Ltd shares had fallen by 26.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Novocure Ltd is $38.00

This summary was machine generated from LSEG data February 27 at 04:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)